LivaNova (LIVN) FCF Margin (2015 - 2026)

LivaNova (LIVN) posted FCF Margin of 1.31% for Q1 2026, down 90.56% sequentially from 13.9% in Q4 2025, and down 285.0% YoY from 0.71% in Q1 2025.

LivaNova (LIVN) FCF Margin (2015 - 2026) Analysis & Trends

LivaNova has reported FCF Margin for 12 years, with the latest figure at 1.31% in Q1 2026.

Quarterly FCF Margin fell 285.0% year-over-year to 1.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11.5% (up 9.0% YoY) and the FY2025 annual result came in at 12.48%, up 164.0% from the prior year.
FCF Margin slipped to 1.31% in Q1 2026 per LIVN's latest filing, from 13.9% in the prior quarter.
Over five years, FCF Margin peaked at 21.22% in Q4 2024 and troughed at 8.03% in Q2 2023.
A 5-year average of 7.27% and a median of 8.58% in 2022 frame the typical range for FCF Margin.
The sharpest annual moves came in 2022 and 2024: FCF Margin tumbled 1371 bps in 2022, then soared 1782 bps in 2024.
Over 5 years, FCF Margin stood at 3.48% in 2022, then soared by 280 bps to 13.23% in 2023, then jumped by 60 bps to 21.22% in 2024, then sank by 35 bps to 13.9% in 2025, then tumbled by 91 bps to 1.31% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 1.31%, 13.9%, and 17.38% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Abbott Laboratories	199.63 Bn	194.02 Bn	7.27 Bn	15.81%
2	Stryker	127.42 Bn	123.95 Bn	4.50 Bn	16.07%
3	Medtronic	118.97 Bn	109.75 Bn	6.41 Bn	21.26%
4	Boston Scientific	73.39 Bn	72.85 Bn	3.85 Bn	23.50%
5	Edwards Lifesciences	51.97 Bn	47.72 Bn	1.35 Bn	33.60%
6	Dexcom	34.32 Bn	32.37 Bn	830.00 Mn	14.10%
7	GE HealthCare Technologies	33.76 Bn	31.65 Bn	2.18 Bn	1.28%
8	Koninklijke Philips	26.35 Bn	23.03 Bn	4.55 Bn	5.32%
9	Steris	23.04 Bn	22.56 Bn	684.20 Mn	18.73%
10	LivaNova	4.31 Bn	3.79 Bn	273.67 Mn	8.97%

Download Data